A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients

Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms. However, a small percentage of the population will become severely ill, and some will succumb to death. The clinical severity of COVID-19 has a close connection to the dysregulation of the p...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-12, Vol.11 (1), p.23491-9, Article 23491
Main Authors: Deb, Chirajyoti, Salinas, Allan N., Zheng, Tianyu, Middleton, Aurea, Kern, Katelyn, Penoyer, Daleen, Borsadia, Rahul, Hunley, Charles, Abomoelak, Bassam, Mehta, Vijay, Irastorza, Laura, Mehta, Devendra I., Huo, Qun
Format: Article
Language:English
Subjects:
631/1647
631/250
631/61
639/638
639/925
692/53
692/699
Blood
Blood tests
Case-Control Studies
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 - pathology
COVID-19 - virology
Gold - chemistry
Humanities and Social Sciences
Humans
Humoral immunity
Immune response
Immune status
Immunity, Humoral
Immunoassay - methods
Immunoglobulin G
Metal Nanoparticles - chemistry
multidisciplinary
Nanoparticles
Patients
Risk Factors
SARS-CoV-2 - isolation & purification
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms. However, a small percentage of the population will become severely ill, and some will succumb to death. The clinical severity of COVID-19 has a close connection to the dysregulation of the patient’s immune functions. We previously developed a simple, nanoparticle-enabled blood test that can determine the humoral immune status in animals. In this study, we applied this new test to analyze the immune function in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected a drastic decrease of humoral immunity in COVID-19 patients who developed moderate to severe symptoms, but not in patients with no or mild symptoms. The new test may be potentially used to monitor the immunity change and predict the clinical risk of patients with COVID-19.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-02863-2